Vaxcyte, Inc. 8-K

What Happened
Vaxcyte, Inc. announced in an 8-K that director Jacks Lee retired from the Board effective June 17, 2026 and, upon his retirement, entered a consulting agreement to advise on global strategic supply and manufacturing operations. On June 17, 2026 the Board appointed Moncef Slaoui as a Class II director, with a term expiring at the Company’s 2028 annual meeting; the Board determined he qualifies as an independent director under Nasdaq Rule 5605(a)(2).

Key Details

• Jacks Lee’s retirement effective June 17, 2026; retirement was not due to any disagreement with the Company.
• Lee immediately began a consulting agreement to serve as a consultant on global strategic supply and manufacturing operations.
• Moncef Slaoui was appointed to the Board on June 17, 2026 as a Class II director; his term expires at the 2028 annual meeting.
• Dr. Slaoui will receive non-employee director compensation under the Company’s Director Compensation Program; the annual equity grant for directors is currently set at an equivalent value of $430,000. The Company entered into its standard indemnification agreement with Dr. Slaoui.

Why It Matters
This filing affects Vaxcyte’s board composition and continuity of expertise: the Board gains a new independent director immediately while retaining Mr. Lee’s operational knowledge through a consulting role focused on supply and manufacturing. Compensation and indemnification terms are standard and disclosed, and the appointment is disclosed as independent with no reportable related-party transactions. Investors should note the governance change and the company’s steps to preserve institutional knowledge around supply and manufacturing.